Academic Background and Problem Statement In recent years, immune checkpoint inhibitors (ICIs) have made significant progress in cancer treatment, particularly anti-PD-1 and anti-PD-L1 antibodies, which have become the standard of care for first-line treatment in various cancers. However, despite the notable clinical activity of these therapies in ...